Early Results: Six Patients Reach Insulin Independence After Islet Cell Transplant

Elodon Pharmaceuticals is testing an approach to Type 1 diabetes management: transplanting islet cells (the insulin-producing cells the immune system attacks in Type 1 diabetes) directly into the liver. All six of the initial participants became insulin independent after receiving these transplants.

The trial is now expanding to include up to 12 participants total. This expansion suggests the early results were promising enough to continue the research, though the full safety and effectiveness data are still being collected.

The key difference in this trial is how the transplanted cells are protected. The researchers use a drug called Tegopoubart, designed to work differently than traditional immunosuppressive medications like tacrolimus, which carry significant side effects.

By using a more targeted protective strategy, researchers hope to help transplanted islet cells survive while reducing the burden of heavy immunosuppression on the body. However, exactly how well this works over time remains to be seen, as the trial is still ongoing.

One participant, identified as patient number nine in the trial, shared her experience online. Within one week of her transplant (received in mid-January), her insulin needs dropped significantly. By one month post-transplant, she reported blood sugar readings spending 99% of the time in her target range, typically between 70 and 115 mg/dL, with fewer extreme highs and lows.

It's important to note that islet cells continue maturing for approximately three months after transplant, meaning improvements may continue over time. One participant's positive early experience is encouraging but represents a single data point from a very small trial.

This trial involves only a handful of people—far too small a group to know whether these results will hold up over time or apply more broadly. Researchers will need to follow participants long-term to understand durability and safety.

The researchers also note that this approach currently isn't fully scalable, meaning there are practical limits to how many people could receive this treatment right now. Further development would be needed to make islet cell transplantation more widely available.

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.